We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

FDA Issues Revised Draft Guidance on Reporting Drug Sample Information Under the ACA

Nancy M. Parsons

Nancy M. Parsons,

Washington, D.C.

22 July 2014
On July 11, FDA issued new draft guidance concerning drug sample reporting mandated under the Affordable Care Act (ACA).  The guidance, Reporting Drug Sample Information Under Section 6004 of the Affordable Care Act, replaces agency’s earlier April 2012 guidance, Compliance Policy on Reporting Drug Sample Distribution Information.  In this new document, the agency provides more detailed direction  to manufacturers and authorized distributors of record submitting sample information under section 6004 of the ACA.  For instance, the guidance provides definitions relevant to drug sample submissions, information on the Electronic Submissions Gateway, and FDA’s interpretation of section 6004, including who should submit the drug information, how it should be submitted, and what information should be included.  It also announces an updated enforcement policy, requiring the submission of data for the 2014 calendar year by April 1, 2015.

To ensure comments are considered before work begins on the final version, comments on the draft should be submitted by October 9, 2014.  The draft guidance is available here.

 

The author thanks Katelyn Ruiz for her assistance.

Nancy M. Parsons

Nancy M. Parsons,

Washington, D.C.

EMA to Revise Herbal Medicines Guideline

On 1 September 2016, the European Medicines Agency ("EMA") opened for public consultation a Draft revision to its Guideline on the assessment of clinical safety and efficacy in the...

08 September 2016
Loading data